1
|
Molyneaux K, Laggner C, Vincent J, Brady-Kalnay S. Small molecule antagonists of PTPmu identified by artificial intelligence-based computational screening block glioma cell migration and growth. PLoS One 2023; 18:e0288980. [PMID: 37494327 PMCID: PMC10370706 DOI: 10.1371/journal.pone.0288980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2022] [Accepted: 07/07/2023] [Indexed: 07/28/2023] Open
Abstract
PTPmu (PTPμ) is a member of the receptor protein tyrosine phosphatase IIb family that participates in both homophilic cell-cell adhesion and signaling. PTPmu is proteolytically downregulated in glioblastoma generating extracellular and intracellular fragments that have oncogenic activity. The intracellular fragments, in particular, are known to accumulate in the cytoplasm and nucleus where they interact with inappropriate binding partners/substrates generating signals required for glioma cell migration and growth. Thus, interfering with these fragments is an attractive therapeutic strategy. To develop agents that target these fragments, we used the AI-based AtomNetⓇ model, a drug design and discovery tool, to virtually screen molecular libraries for compounds able to target a binding pocket bordered by the wedge domain, a known regulatory motif located within the juxtamembrane portion of the protein. Seventy-four high-scoring and chemically diverse virtual hits were then screened in multiple cell-based assays for effects on glioma cell motility (scratch assays) and growth in 3D culture (sphere assays), and PTPmu-dependent adhesion (Sf9 aggregation). We identified three inhibitors (247678835, 247682206, 247678791) that affected the motility of multiple glioma cell lines (LN229, U87MG, and Gli36delta5), the growth of LN229 and Gli36 spheres, and PTPmu-dependent Sf9 aggregation. Compound 247678791 was further shown to suppress PTPmu enzymatic activity in an in vitro phosphatase assay, and 247678835 was able to inhibit the growth of human glioma tumors in mice. We propose that these three compounds are PTPmu-targeting agents with therapeutic potential for treating glioblastoma.
Collapse
Affiliation(s)
- Kathleen Molyneaux
- Department of Molecular Biology & Microbiology, Case Western Reserve University, Cleveland, Ohio, United States of America
| | | | - Jason Vincent
- Department of Molecular Biology & Microbiology, Case Western Reserve University, Cleveland, Ohio, United States of America
| | - Susann Brady-Kalnay
- Department of Molecular Biology & Microbiology, Case Western Reserve University, Cleveland, Ohio, United States of America
| |
Collapse
|
2
|
Johansen ML, Perera R, Abenojar E, Wang X, Vincent J, Exner AA, Brady-Kalnay SM. Ultrasound-Based Molecular Imaging of Tumors with PTPmu Biomarker-Targeted Nanobubble Contrast Agents. Int J Mol Sci 2021; 22:1983. [PMID: 33671448 PMCID: PMC7922223 DOI: 10.3390/ijms22041983] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Revised: 02/08/2021] [Accepted: 02/11/2021] [Indexed: 11/16/2022] Open
Abstract
Ultrasound imaging is a widely used, readily accessible and safe imaging modality. Molecularly-targeted microbubble- and nanobubble-based contrast agents used in conjunction with ultrasound imaging expand the utility of this modality by specifically targeting and detecting biomarkers associated with different pathologies including cancer. In this study, nanobubbles directed to a cancer biomarker derived from the Receptor Protein Tyrosine Phosphatase mu, PTPmu, were evaluated alongside non-targeted nanobubbles using contrast enhanced ultrasound both in vitro and in vivo in mice. In vitro resonant mass and clinical ultrasound measurements showed gas-core, lipid-shelled nanobubbles conjugated to either a PTPmu-directed peptide or a Scrambled control peptide were equivalent. Mice with heterotopic human tumors expressing the PTPmu-biomarker were injected with PTPmu-targeted or control nanobubbles and dynamic contrast-enhanced ultrasound was performed. Tumor enhancement was more rapid and greater with PTPmu-targeted nanobubbles compared to the non-targeted control nanobubbles. Peak tumor enhancement by the PTPmu-targeted nanobubbles occurred within five minutes of contrast injection and was more than 35% higher than the Scrambled nanobubble signal for the subsequent two minutes. At later time points, the signal in tumors remained higher with PTPmu-targeted nanobubbles demonstrating that PTPmu-targeted nanobubbles recognize tumors using molecular ultrasound imaging and may be useful for diagnostic and therapeutic purposes.
Collapse
Affiliation(s)
- Mette L. Johansen
- Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-4960, USA; (M.L.J.); (J.V.)
| | - Reshani Perera
- Department of Radiology, Case Western Reserve University, Cleveland, OH 44106-4960, USA; (R.P.); (E.A.)
| | - Eric Abenojar
- Department of Radiology, Case Western Reserve University, Cleveland, OH 44106-4960, USA; (R.P.); (E.A.)
| | - Xinning Wang
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106-7207, USA;
| | - Jason Vincent
- Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-4960, USA; (M.L.J.); (J.V.)
| | - Agata A. Exner
- Department of Radiology, Case Western Reserve University, Cleveland, OH 44106-4960, USA; (R.P.); (E.A.)
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106-7207, USA;
| | - Susann M. Brady-Kalnay
- Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, 10900 Euclid Ave, Cleveland, OH 44106-4960, USA; (M.L.J.); (J.V.)
| |
Collapse
|
3
|
Vincent J, Craig SEL, Johansen ML, Narla J, Avril S, DiFeo A, Brady-Kalnay SM. Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts. Diagnostics (Basel) 2021; 11:diagnostics11020181. [PMID: 33513911 PMCID: PMC7911696 DOI: 10.3390/diagnostics11020181] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2020] [Revised: 01/08/2021] [Accepted: 01/15/2021] [Indexed: 12/31/2022] Open
Abstract
Background: We developed a fluorophore-conjugated peptide agent, SBK4, that detects a tumor-specific proteolyzed form of the cell adhesion molecule, PTPmu, found in the tumor microenvironment. We previously demonstrated its tissue specific distribution in high-grade brain tumors. To extend those studies to other aggressive solid tumor types, we assessed the tissue distribution of PTPmu/SBK4 in a set of matched gynecologic cancer patient derived xenografts (PDXs) and primary patient tumors, as well as a limited cohort of tumors from gynecological cancer patients. PDXs isolated from the tissues of cancer patients have been shown to yield experimentally manipulatable models that replicate the clinical characteristics of individual patients’ tumors. In this study, gynecological cancer PDXs and patient biopsies were examined to determine if tumor-specific proteolyzed PTPmu was present. Methods: We used the peptide agent SBK4 conjugated to the fluorophore Texas Red (TR) to label tumor tissue microarrays (TMAs) containing patient and/or PDX samples from several high-grade gynecologic cancer types, and quantified the level of staining with Image J. In one TMA, we were able to directly compare the patient and the matched PDX tissue on the same slide. Results: While normal tissue had very little SBK4-TR staining, both primary tumor tissue and PDXs have higher labeling with SBK4-TR. Matched PDXs and patient samples from high-grade endometrial and ovarian cancers demonstrated higher levels of PTPmu by staining with SBK4 than normal tissue. Conclusion: In this sample set, all PDXs and high-grade ovarian cancer samples had increased labeling by SBK4-TR compared with the normal controls. Our results indicate that proteolyzed PTPmu and its novel peptide detection agent, SBK4, allow for the visualization of tumor-specific changes in cell adhesion molecules by tissue-based staining, providing a rationale for further development as an imaging agent in aggressive solid tumors, including gynecological cancers.
Collapse
Affiliation(s)
- Jason Vincent
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA; (J.V.); (S.E.L.C.); (M.L.J.)
| | - Sonya E. L. Craig
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA; (J.V.); (S.E.L.C.); (M.L.J.)
| | - Mette L. Johansen
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA; (J.V.); (S.E.L.C.); (M.L.J.)
| | - Jyosthna Narla
- Department of Pathology, Alexian Brothers Hospital, San Jose, CA 95116, USA;
| | - Stefanie Avril
- Department of Pathology and the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA;
| | - Analisa DiFeo
- Department of Pathology and Department of Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI 48109, USA;
| | - Susann M. Brady-Kalnay
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH 44106, USA; (J.V.); (S.E.L.C.); (M.L.J.)
- Department of Pathology and the Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA;
- Correspondence: ; Tel.: +1-216-368-0330
| |
Collapse
|
4
|
Covarrubias G, Johansen ML, Vincent J, Erokwu BO, Craig SEL, Rahmy A, Cha A, Lorkowski M, MacAskill C, Scott B, Gargesha M, Roy D, Flask CA, Karathanasis E, Brady-Kalnay SM. PTPmu-targeted nanoparticles label invasive pediatric and adult glioblastoma. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2020; 28:102216. [PMID: 32413511 DOI: 10.1016/j.nano.2020.102216] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/24/2019] [Revised: 04/07/2020] [Accepted: 04/21/2020] [Indexed: 12/18/2022]
Abstract
Poor prognosis for glioblastoma (GBM) is a consequence of the aggressive and infiltrative nature of gliomas where individual cells migrate away from the main tumor to distant sites, making complete surgical resection and treatment difficult. In this manuscript, we characterize an invasive pediatric glioma model and determine if nanoparticles linked to a peptide recognizing the GBM tumor biomarker PTPmu can specifically target both the main tumor and invasive cancer cells in adult and pediatric glioma models. Using both iron and lipid-based nanoparticles, we demonstrate by magnetic resonance imaging, optical imaging, histology, and iron quantification that PTPmu-targeted nanoparticles effectively label adult gliomas. Using PTPmu-targeted nanoparticles in a newly characterized orthotopic pediatric SJ-GBM2 model, we demonstrate individual tumor cell labeling both within the solid tumor margins and at invasive and dispersive sites.
Collapse
Affiliation(s)
- Gil Covarrubias
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | - Mette L Johansen
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH
| | - Jason Vincent
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH
| | | | - Sonya E L Craig
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH
| | - Abdelrahman Rahmy
- Department of Chemistry, Case Western Reserve University, Cleveland, OH
| | - Anthony Cha
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | - Morgan Lorkowski
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH
| | | | | | | | | | - Chris A Flask
- Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH; Department of Radiology, Case Western Reserve University, Cleveland, OH; Department of Pediatrics, Case Western Reserve University, Cleveland, OH
| | | | - Susann M Brady-Kalnay
- Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, OH; Department of Neurosciences, Case Western Reserve University, Cleveland, OH.
| |
Collapse
|